Epizyme Inc. (NASDAQ:EPZM) shares saw unusually-high trading volume on Tuesday . Approximately 370,978 shares changed hands during trading, an increase of 4% from the previous session’s volume of 356,743 shares.The stock last traded at $8.61 and had previously closed at $8.72.

EPZM has been the topic of several research analyst reports. Mizuho cut their price target on Epizyme from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, May 10th. HC Wainwright reaffirmed a “buy” rating on shares of Epizyme in a research report on Tuesday, August 9th. Cowen and Company reaffirmed a “buy” rating on shares of Epizyme in a research report on Monday, June 20th. Zacks Investment Research lowered Epizyme from a “buy” rating to a “hold” rating in a research report on Wednesday, May 11th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a $26.00 price target on shares of Epizyme in a research report on Monday, June 20th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. Epizyme has an average rating of “Buy” and a consensus target price of $23.11.

The firm’s 50 day moving average price is $9.83 and its 200-day moving average price is $10.44. The firm’s market cap is $494.94 million.

Epizyme (NASDAQ:EPZM) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.03. Analysts anticipate that Epizyme Inc. will post ($2.19) EPS for the current year.

In other news, insider Robert A. Copeland sold 4,000 shares of the firm’s stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $10.37, for a total transaction of $41,480.00. Following the sale, the insider now owns 35,538 shares of the company’s stock, valued at approximately $368,529.06. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

A hedge fund recently bought a new stake in Epizyme stock. California Public Employees Retirement System purchased a new position in shares of Epizyme Inc. (NASDAQ:EPZM) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund purchased 170,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,723,000. California Public Employees Retirement System owned about 0.41% of Epizyme as of its most recent SEC filing.

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.